Initial clinical characterization of novel proximal biomarkers for Nx-1607, a first-inclass oral Cbl-B inhibitor, in patients with advanced malignancies
Authors
Whelan, S.Karim, C.
Ye, J.
Ingallinera, T.
Cherala, G.
Jameson, K.
Williams, A.
Sharp, A.
Krebs, Matthew G
Pacey, S.
Blagden, S.
Plummer, R.
Hochhauser, D.
Evans, J.
De Bono, J.
Powers, J.
Affiliation
Nurix Therapeutics, Inc., San Francisco, CA,Issue Date
2022
Metadata
Show full item recordCitation
Whelan S, Karim C, Ye J, Ingallinera T, Cherala G, Jameson K, et al. Initial Clinical Characterization of Novel Proximal Biomarkers for Nx-1607, a First-Inclass Oral Cbl-B Inhibitor, in Patients with Advanced Malignancies. Journal for immunotherapy of cancer. 2022 Nov;10:A809-A. PubMed PMID: WOS:000919423400733.Journal
Journal for Immunotherapy of CancerDOI
10.1136/jitc-2022-SITC2022.0777Additional Links
https://dx.doi.org/10.1136/jitc-2022-SITC2022.0777Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1136/jitc-2022-SITC2022.0777